Publications by authors named "Tatiana Adams"
Article Synopsis
- * Results showed that 7.7% of patients had a durable partial response, with 80.8% experiencing stable disease, but the study did not achieve its goal of four responses.
- * The findings confirmed the safety of the treatment, and while promising, suggested that more structured randomized trials may be needed due to chordoma's rarity and low response rates.
Background: MVA-BN-brachyury-TRICOM is a recombinant vector-based therapeutic cancer vaccine designed to induce an immune response against brachyury. Brachyury, a transcription factor overexpressed in advanced cancers, has been associated with treatment resistance, epithelial-to-mesenchymal transition, and metastatic potential. MVA-BN-brachyury-TRICOM has demonstrated immunogenicity and safety in previous clinical trials of subcutaneously administered vaccine.
View Article and Find Full Text PDFRespiratory disease caused by RSV infection is recognized as a severe public health issue in infants, young children and elderly with no specific treatment option. Vaccination may be the most effective strategy to combat this highly infectious virus although no vaccine has been approved. The novel vaccine candidate MVA-BN-RSV encodes RSV surface proteins F and G (subtypes A, B) as well as internal proteins N and M2 in the MVA-BN viral vector backbone to provide broad protection against RSV.
View Article and Find Full Text PDF